drapeau fr drapeau en

GamaMabs Pharma, a company incorporated in 2013, has licensed programs developed by LFB Biotechnologies.

With the objective of developing monoclonal antibodies for the treatment of cancer, GamaMabs Pharma owns the rights to a monoclonal antibody generation platform (Emabling®) and to a pipeline of several antibodies derived from this technology, the main one, 3C23K in pre-clinical phase, targeting AMHR2 in ovarian cancer.

Nicolas Olivès

Participation: minoritaire 

Development of monoclonal antibodies for the treatment of cancer

Stéphane Degrove & Gérard Tiraby

IXO intervention: 1,05 M€

Sales figures: N.C.

Effective: N.C.